Table 2.
Clinical Data for Patient Groups
| COVIDreduced | COVIDnormal | P value | |
|---|---|---|---|
| Perception of recovery (% of normal) | 70 (60–80) | 98 (90–100) | <0.001* |
| 6‐min walk distance (m) | 470±87 | 560±117 | 0.0089* |
| Duration from discharge to MR‐CPET (d) | 97 (80–116) | 115 (96–151) | 0.068 |
| Severity of acute COVID‐19 illness | |||
| Length of admission (d) | 3.5 (1.0–5.2) | 4.0 (0.8–5.0) | 0.87 |
| Severity score | 4.0 (2.0–4.0) | 4.0 (2.0–4.0) | 0.69 |
| Peak d‐dimer, ng/mL | 576 (373–1160) | 496 (463–1020) | 0.91 |
| Peak CRP, mg/L | 64 (21–116) | 45 (23–133) | 0.95 |
| Current investigations | |||
| FEV1 (% predicted) | 97 (91–102) | 93 (88–100) | 0.49 |
| FVC (% predicted) | 88 (79–93) | 80 (76–93) | 0.39 |
| Hemoglobin, g/L | 141±13 | 137±16 | 0.42 |
| Creatinine, μmol/L | 73±13 | 67±15 | 0.16 |
| CK, units/L | 93 (71–110) | 107 (73–157) | 0.29 |
| NT‐proBNP, ng/L | 49 (49–122) | 49 (49–64) | 0.38 |
Normally distributed data displayed as mean±SD and non‐normally distributed data shown as median (interquartile range). CK indicates creatine kinase; COVIDnormal, normal exercise capacity following COVID‐19; COVIDreduced, reduced exercise capacity following COVID‐19; CRP, C‐reactive protein; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MR‐CPET, magnetic resonance–augmented cardiopulmonary exercise test; and NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
*
Significant difference between post‐COVID‐19 patient groups.